A Phase I/IIa Study to Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment in Patients With Solid Tumor
Phase of Trial: Phase I/II
Latest Information Update: 23 Aug 2018
Price : $35 *
At a glance
- Drugs MG-D-1509 (Primary) ; MG-005; Sorafenib
- Indications Liver cancer; Lung cancer; Renal cancer; Solid tumours
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Metagone Biotech
- 15 Aug 2018 Status changed from not yet recruiting to recruiting.
- 20 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Jun 2018.
- 30 Jan 2018 New trial record